Small Molecule Drug Development Core Facility (SMDD Core) has the automation equipment, libraries, and experienced personnel to support a wide range of assay ...

- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor ...

Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...

“The cleverer I am about miniaturizing the world, the better I am at possessing it.” That line of thinking, as practiced in nanoscale engineering, has no stronger embodiment today than ChemLex’s newly ...

- Maintenance formulation of small molecule ASC30 demonstrated an observed half-life of 75 days in participants with obesity in the U.S. Phase Ib study. - 75-day observed half-life supports ...

Fungal infections kill millions of people each year, and modern medicine is struggling to keep up. But researchers at ...

WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that ...

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous (SQ) depot formulation of ...